ProKidney Corp. (PROK)

US — Healthcare Sector
Peers: RVMD  NUVL  RAPT  SNDX  ALVO  ROIV  GBTG  STGW 

Automate Your Wheel Strategy on PROK

With Tiblio's Option Bot, you can configure your own wheel strategy including PROK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PROK
  • Rev/Share 0.0024
  • Book/Share 2.8686
  • PB -0.6691
  • Debt/Equity -0.0034
  • CurrentRatio 10.9626
  • ROIC -0.4942

 

  • MktCap 1522754913.0
  • FreeCF/Share -1.1706
  • PFCF -10.0857
  • PE -9.7635
  • Debt/Assets 0.0083
  • DivYield 0
  • ROE 0.0694

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade PROK BofA Securities Neutral Underperform -- $1 June 30, 2025
Initiation PROK JP Morgan -- Neutral -- -- Sept. 30, 2024
Initiation PROK Guggenheim -- Buy -- $6 Sept. 10, 2024

News

PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
PROK
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.

Read More
image for news PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
PROK
Published: July 09, 2025 by: Yahoo Finance
Sentiment: Positive

Morning Brief, Market Sunrise anchor Ramzan Karmali breaks down the latest international news for July 9, 2025. President Trump stated on a social media post that tariffs will start being paid on August 1st and that date will not change.

Read More
image for news Trump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%
Why Is Penny Stock ProKidney Trading Higher On Tuesday?
PROK
Published: July 08, 2025 by: Benzinga
Sentiment: Positive

ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.

Read More
image for news Why Is Penny Stock ProKidney Trading Higher On Tuesday?
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
PROK
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

WINSTON-SALEM, N.C., July 01, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced the completion of the domestication process to change the jurisdiction of incorporation of the Company from the Cayman Islands to Delaware. The domestication was approved by shareholders of the Company at its Annual General Meeting held on May 29, 2025. Effective as of July 1, 2025, each (i) Class A ordinary share automatically converted into one share of Class A common stock of ProKidney Corp., a Delaware corporation and …

Read More
image for news ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
PROK
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive

PROKIDNEY CP (PROK) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Read More
image for news Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)

About ProKidney Corp. (PROK)

  • IPO Date 2021-06-30
  • Website https://www.prokidney.com
  • Industry Biotechnology
  • CEO Bruce Culleton
  • Employees 204

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.